TVAX Biomedical is developing a paradigm-shifting cancer treatment that offers the promise of improved clinical outcomes and low toxicity and the potential for fundamentally changing the way cancer is treated.
TVAX Immunotherapy is a unique personalized combination of cancer cell vaccination and “killer” T cell treatment – two separate approaches that have each demonstrated limited therapeutic potential, though neither has the efficacy to be a viable standalone treatment. This treatment has demonstrated the potential to effectively treat numerous cancers without many of the undesirable side effects associated with radiation and chemotherapy. The key distinction between TVAX and other cancer immunotherapy companies is that TVAX uses both cancer vaccination and activated "killer" T cell treatment in one treatment platform. To learn more, click here.
TVAX’s lead candidate (TVI-Brain-1) is currently being evaluated for the treatment of brain cancer and targets glioblastomas. The company has been authorized by the United States Food and Drug Administration (FDA) to conduct pivotal Phase 3 trials for TVI-Brain-1 to support the therapy’s potential FDA approval. To learn more, click here.